What is INKT's current stock price?

INKT (MiNK Therapeutics, Inc.) is currently trading at $10.87 with a market cap of $54.2M.

What sector is MiNK Therapeutics, Inc. in?

MiNK Therapeutics, Inc. (INKT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is INKT a good stock to buy?

Analysts have a Buy consensus on INKT with a price target of $35.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

INKT MiNK Therapeutics, Inc.

Healthcare

$10.87-0.64%ClosedMarket Cap: $54.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-4.11

P/S

0.00

EV/EBITDA

-3.59

DCF Value

$3,126.92

FCF Yield

-3207.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

76.0%

ROA

-120.2%

ROIC

-415.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-2.7M	$—
Q4 null	$0.00	$-2.6M	$—
FY null	$0.00	$-12.5M	$—
Q3 null	$0.00	$-2.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$35.00

Target (Median)

$35.00

Target Range

$35.00 - $35.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-18

HC Wainwright & Co.Buy

2026-04-01

HC Wainwright & Co.Buy

2025-08-15

HC Wainwright & Co.Neutral

2025-07-15

William BlairMarket Perform

2025-07-14

Trading Activity

Insider Trades

View All

Holcomb John Bradleydirector

SellThu Apr 30

Orilall Melissaofficer: Principal Financial Officer

SellThu Apr 09

Charette Austinofficer: Principal Accounting Officer

SellMon Mar 23

Ryan Barbaradirector

SellWed Mar 11

Ryan Barbaradirector

SellWed Mar 11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.47

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Peers